ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1657

Mapping the Network of Coordinated Immune Dysregulation in Juvenile Dermatomyositis at Single-cell Resolution

Gabrielle Rabadam1, Camilla Wibrand2, Emily Flynn1, George Hartoularos1, Yang Sun1, Susan Kim3, Chun Jimmie Ye1, Zev Gartner1, Marina Sirota4 and Jessica Neely1, 1University of California San Francisco, San Francisco, CA, 2Aarhus University, Aarhus, Denmark, and University of California San Francisco, San Francisco, CA, 3UCSF Benioff Children's Hospital, San Francisco, CA, 4Bakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, CA

Meeting: ACR Convergence 2023

Keywords: autoimmune diseases, Bioinformatics, dermatomyositis, Genomics and Proteomics

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 13, 2023

Title: Abstracts: Pediatric Rheumatology – Basic Science

Session Type: Abstract Session

Session Time: 4:00PM-5:30PM

Background/Purpose: Juvenile Dermatomyositis (JDM) is a rare multisystem autoimmune condition that involves complex immune responses in both innate and adaptive compartments. Currently, we have a limited systems-level understanding of how cellular immunophenotypes functionally cooperate and are dysregulated in JDM. Increasing knowledge of the immune regulatory networks associated with JDM could lead to identification of precision treatment strategies and biomarkers.

Methods: We used multiplexed single cell RNA sequencing to profile 27 peripheral blood samples from JDM patients (n=15, samples=22) and healthy pediatric controls (n=5, HCs). We performed standard processing, dimensional reduction, and clustering steps to identify 6 major cell types (B, CD4T, CD8T, gdT, NK & Myeloid). We applied an unsupervised network inference method, DECIPHERseq, which uses non-negative matrix factorization to identify coordinated regulatory networks of functional gene expression programs (GEPs) across cell types and community detection to identify hubs or ‘modules’ of GEPs. The network was annotated using 1) gene set enrichment analysis to identify pathways overrepresented in each program and 2) the DECIPHERseq enrichment method, which relies on resampling to identify gene sets enriched within modules compared to the rest of the network. To determine JDM disease activity-associated changes in network structure, we performed ANOVA on mean patient expression of GEPs between treatment-naive (TN), active, and inactive JDM, and HC samples.

Results: We analyzed ~110,000 cells. DECIPHERseq inferred a network of 76 activity programs that formed 6 modules. All modules contained multiple cell types, highlighting that biological processes are coordinated across many cell types in JDM. Module enrichment analysis revealed consensus biological themes for each GEP hub. Module 1 was enriched in type I IFN responses and many programs in this module were increased in TN-JDM, as expected. Several disease-associated programs were highly correlated to this central IFN hub suggesting these cell-specific responses may be either up or downstream of IFN signaling. These included NK12, a proliferative NK program (MKI67, HIST1H1B); gdT4, a cytotoxic Th1 polarized gdT program (GZMB, CX3CR1, TBX21); CD4T10, an activated and proliferative Treg program (FOXP3, IL2RA, PRDM1, MKI67); and B9, an immature naïve B cell program (CD9, TCL1A, CD24), all of which were expressed higher in TN-JDM. Module 2, enriched in ribosomal processes, and Module 5, enriched in stress responses and regulation of cell death, were negatively correlated with Module 1.Several programs within Modules 2 and 5 were expressed significantly lower in TN-JDM suggesting dysfunction of these cellular processes in new-onset disease.

Conclusion: By employing unsupervised network analyses, we identified a central IFN hub highly correlated with novel cell-specific GEPs as well as dysfunction of ribosome and cell stress responses across many cell types in TNJDM. This systems-level perspective highlights coordinated peripheral immune responses that are both over- and underactive in JDM providing a foundation for future work to identify therapies to reprogram this dysregulation.

Supporting image 1

Fig. 1: A) Table showing samples included from JDM donors (n=15) and HCs. Some patients with JDM have longitudinal samples with a change in disease activity level included. B) UMAP reduction showing major immune cell types in peripheral blood samples annotated based on canonical markers. C) Overview of the DECIPHERseq workflow. Briefly, major cell types are subsetted and reduced via non-negative matrix factorization (NMF) into a set of GEPs defined by gene loadings quantifying the contribution of individual genes to that GEP and cell loadings quantifying how strongly expressed that GEP is in each cell. Cell loadings are averaged per PBMC sample and pairwise correlations are calculated between all the programs to identify co-varying GEPs. D) Heatmap showing 6 “blocks” (Modules 1-6) identified by DECIPHERseq from all pairwise correlations of GEPs across 6 major cell types. GEPs are clustered into modules using a Constant Potts Model for community detection, with isolated GEPs filtered out (greyscale).

Supporting image 2

Fig. 2: A) Force-directed network graph (top) constructed from correlated GEPs in PBMCs from JDM patients and healthy controls, where strongly positively correlated programs appear closer and strongly anti-correlated programs appear further apart. Nodes represent biological activity programs in the given cell types and plotted edges represent significantly positively correlated activity programs (Pearson, p<0.05). Modules were identified using a Constant Potts Model for community detection. Module labels were annotated from the top 20 gene sets significantly enriched for each module relative to the rest of the network (module enrichment p < 0.05). Selected network modules (bottom) are colored by FDR of enrichment for indicated gene ontology set. B) Subsetted heatmap highlighting the negative correlations between Module 1 and Modules 2 and 5. C) Network graph of activity programs in PBMCs, colored by the relative effect size (linear scale) calculated by 4 group ANOVA of disease activity categorized by TN-JDM, active JDM, inactive JDM, and HCs. Significance level is indicated by node size.

Supporting image 3

Fig. 3: A) Diagram showing GEPs in Module 1, indicating IFN hub-associated programs B9, CD4T10, gdT4, and NK10. B) Dotplot comparing top 10 enriched gene ontology (GO) sets for each program (FDR < 0.01). C) Boxplots for indicated disease-associated programs (4 group ANOVA, p < 0.05). Significant post-hoc pairwise comparisons between groups (Tukey HSD) are shown as * p<0.05, ** p<0.01, ***<0.001 (BH adjusted p value).


Disclosures: G. Rabadam: 23andMe, 7; C. Wibrand: AMBU, 11, GenMab, 11, Lundbeck, 11, NovoNordisk, 11; E. Flynn: None; G. Hartoularos: None; Y. Sun: None; S. Kim: None; C. Ye: Chan Zuckerberg Initiative, 5, Genentech, 5, ImmunAI, 1, 8, Maze Therapeutics, 2, 8, Related Sciences, 1, 8, TReX Bio, 2; Z. Gartner: Scribe Biosciences, 1, 8, Serotiny, 1, 8; M. Sirota: Exxagen, 1; J. Neely: None.

To cite this abstract in AMA style:

Rabadam G, Wibrand C, Flynn E, Hartoularos G, Sun Y, Kim S, Ye C, Gartner Z, Sirota M, Neely J. Mapping the Network of Coordinated Immune Dysregulation in Juvenile Dermatomyositis at Single-cell Resolution [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/mapping-the-network-of-coordinated-immune-dysregulation-in-juvenile-dermatomyositis-at-single-cell-resolution/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mapping-the-network-of-coordinated-immune-dysregulation-in-juvenile-dermatomyositis-at-single-cell-resolution/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology